Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with a Suboptimal Response to Previous Disease-Modifying Therapies (1-Year Interim Results)

Patrick Vermersch, Juha-Pekka Erälinna, Richard Nicholas, Celia Oreja-Guevara, Aksel Siva, Bart Van Wijmeersch, Heinz Wiendl, Regine Buffels, Robert Kuhelj, Wei Wei